Table 2.
Autoantibody and disease features of patients with the five major autoantibodies against citrullinated protein profiles a
| Group | n | Anti-CCP2+ b (%) | RF+ (%) | Mean ACPA level (U/ml) | Mean number of citrullinated antigens recognized (range) c,d | (Ex-) smokers (%) e | SE+ f (%) d | VAS median g |
|---|---|---|---|---|---|---|---|---|
| C |
15 |
100 |
93 |
4630 |
6 (1 to 16) |
38 |
93 |
34 |
| D |
83 |
88 |
87 |
1317 |
3 (1 to 13) |
59 |
80 |
35 |
| E |
30 |
87 |
87 |
861 |
2 (0 to 5) |
66 |
70 |
34 |
| F |
198 |
31 |
45 |
137 |
0 (0 to 4) |
49 |
53 |
40 |
| H | 17 | 0 | 29 | 14 | 0 (0 to 1) | 60 | 29 | 50 |
aACPA: anticitrullinated protein antibody; CCP2: cyclic citrullinated peptide 2; RF: rheumatoid factor; SE: shared epitope; VAS: Visual Analogue Scale score. bMeasured using the anti-CCP2 test (CCPlus Immunoscan assay). cReactivity is based upon cutoff values determined with reactivity of healthy individuals with surface plasmon resonance imaging. dP-value < 0.01. eP-value = 0.278. fAt least one SE allele. gP-value = 0.958. Group differences were tested using the Kruskal-Wallis test or Pearson’s χ2 test.